Capsida Biotherapeutics

Peter Anastasiou, CEO 

Oct. 11 | 11:00am | Rentschler ATMP Ballroom 

Thousand Oaks, CA 


Capsida Biotherapeutics is an industry-leading gene therapy company creating a new class of targeted, non-invasive gene therapies for patients with debilitating and life-threatening disorders. Capsida Biotherapeutics has designed one of the industry’s only fully integrated, end-to-end gene therapy solutions. Our high throughput platform biologically screens and identifies engineered capsids to significantly improve target specificity and penetration in disease tissues and cells, to support the use of gene therapy in both rare and common diseases across all ages. Built through a combination of in-house R&D and industry partnerships, our therapeutic approaches – including gene replacement and gene editing – are designed to bring therapies to patients with both monogenic and polygenic diseases. Since our inception in 2019 by Versant Ventures and Westlake Village BioPartners, we have entered into strategic collaborations with AbbVie, CRISPR Therapeutics and Eli Lilly to bring our innovative gene therapies to patients with debilitating and life-threatening disorders. 

By using this website you agree to accept our Privacy Policy and Terms & Conditions